Trond Leren's groupCellular cholesterol metabolism

Trond P. LerenGroup leader
Trond P. Leren
Group leader

High levels of plasma LDL cholesterol as well as other dyslipidemias are major risk factors for coronary heart disease. It has been well documented that lowering the levels of plasma LDL cholesterol by dietary or pharmacological measures reduces the risk for coronary heart disease. The most widely used lipid-lowering drugs are the statins which may lower the levels of plasma LDL cholesterol by 50%. However, because of side effects which prevent a certain proportion of the population from using statins, and the failure to achive sufficient LDL cholesterol reductions in severely hypercholesterolemic subjects, there is a need to develop other lipid-lowering strategies. To this end, there is a need to characterize the cellular cholesterol metabolism in order to identify pathways that could be the target for lipid-lowering strategies.


Research projects:

  • PCSK9-mediated degradation of the LDL receptors
  • Structure-function relationship of lysosomal acid lipase
  • Role of kinases in the expression of the LDL receptors
  • Identification of novel genes involved in lipid metabolism
  • Intracellular cholesterol transport

Contact information
Group leader Trond P. Leren, Department of Medical Genetics, Tel: +47 23026389

Page visits: 844